Nerissa Kreher, MD, MBA

Title: Chief Medical Officer

Organization: Entrada Therapeutics

Bio: Nerissa C. Kreher, MD, MBA is an accomplished physician executive and pediatric endocrinologist with strong biotech experience in Clinical Development and Medical Affairs. Her expertise is in the development of therapies for patients with rare diseases across multiple therapeutic areas. She has participated in corporate growth of multiple biotech companies via VC fundraising events as well as IPOs. She previously served as CMO at Tiburio Therapeutics and AVROBIO. Currently, Nerissa is the Chief Medical Officer at Entrada Therapeutics and serves on the Board of Directors of Rezolute Bio.

2023 FUTURES: RNA targeted Therapeutics Sessions Part 2

Continued updates from relevant companies in the space. These presentations will be followed by a moderated Q&A opportunity.

Mark Stahl, MD, PhD

Senior Medical Director, Clinical Development

Avidity Biosciences

See more from same speaker

Nerissa Kreher, MD, MBA

Chief Medical Officer

Entrada Therapeutics

See more from same speaker

Jane Larkindale, DPhil

VP of Clinical Science PepGen

See more from same speaker

Dania Porco, MS, MBA, CGC

Director in Clinical Science BioMarin Pharmaceutical Inc.

See more from same speaker

Michael Tillinger, MD

VP of Clinical Development Wave Life Sciences

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years

Exon Skipping and Read Through Agents Panel

A brief introduction on the rationale behind mechanisms of endogenous dystrophin restoration, like exon skipping and read through agent therapies, followed by critical information and updates from the companies in this space. Moderated discussion included.

Barry Byrne, MD, PhD

Professor and Associate Chair

University of Florida, Department of Pediatrics

See more from same speaker

Jay Chauhan, PharmD

Medical Science Liaison

NS Pharma

See more from same speaker

Brett Crawford, PhD

Executive Director and Head of the Musculoskeletal Therapeutic Area

BioMarin Pharmaceutical Inc.

See more from same speaker

Ash Dugar, PhD

Senior Vice President, Medical Affairs

Dyne Therapeutics

See more from same speaker

Xiao Shelley Hu, PhD, MS

VP

Wave Life Sciences

See more from same speaker

Matthew Klein, M.D., M.S., FACS

Chief Operating Officer

PTC Therapeutics

See more from same speaker

Nerissa Kreher, MD, MBA

Chief Medical Officer

Entrada Therapeutics

See more from same speaker

James McArthur, PhD

President and Chief Executive Officer

PepGen

See more from same speaker

Mark Stahl, MD, PhD

Senior Medical Director, Clinical Development

Avidity Biosciences

See more from same speaker

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 years